Inhibition of protein kinase C by dequalinium analogues: Structure-activity studies on head group variations

Bioorganic and Medicinal Chemistry

Volumn 14, Issue 23, 2006, Pages 7796-7803

  Abeywickrama, Chandima ^a,b   Rotenberg, Susan A ^a,b   Baker, Arthur David ^a,b  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Head group role; PKC Inhibition; Quinolinium analogues; Substituent effects

Indexed keywords

1,10 (1,10 DECANEDIYL)BIS(1 AMINOISOQUINOLINIUM)DIIODIDE; 1,10 (1,10 DECANEDIYL)BIS(2 AMINO 1 METHYLBENZMETHYLBENZIMIDAZOLIUM); 1,10 (1,10 DECANEDIYL)BIS(2 METHYLBENZOTHIAZOLIUM)DIIODIDE; 1,10 (1,10 DECANEDIYL)BIS(2 METHYLBENZOXAZOLIUM)DIIODIDE; 1,10 (1,10 DECANEDIYL)BIS(2 METHYLQUINOLINIUM)DIIODIDE; 1,10 (1,10 DECANEDIYL)BIS(4 AMINO 2 METHYLQUINOLINIUM)DIIODIDE; 1,10 (1,10 DECANEDIYL)BIS(4 AMINOQUINOLINIUM)DIIODIDE; 1,10 (1,10 DECANEDIYL)BIS(4 N,N DIMETHYLAMINOQUINOLINIUM)DIIODIDE; 1,10 (1,10 DECANEDIYL)BIS(QUINOLINIUM)DIIODIDE; 1,6 BIS[N (1 METHYLQUINOLINIUM 2 METHYL)AMINO]HEXANE DIIODIDE; DEQUALINIUM DERIVATIVE; NITROGEN; PROTEIN KINASE C ALPHA; PROTEIN KINASE C INHIBITOR; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ARTICLE; CORRELATION ANALYSIS; DRUG SYNTHESIS; ENZYME INHIBITION; STRUCTURE ACTIVITY RELATION;

DEQUALINIUM; DRUG DESIGN; ELECTRONS; HUMANS; HYDROCARBONS, AROMATIC; PROTEIN KINASE C-ALPHA; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33750044592     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.07.067     Document Type: Article

References (37)

1. Rotenberg S.A., and Weinstein I.B. In: Pretlow II T.G., and Pretlow T.P. (Eds). Biochemical and Molecular Aspects of Selected Cancers Vol. 1 (1991), Academic Press, Orlando 25-73
2. Rotenberg S.A., Zhu J., Hansen H., Li X., Sun X., Michels C.A., and Riedel H. J. Biochem. 124 (1998) 756
3. Krauss R.S., Housey G.M., Hsiao W.L.W., Johnson M.K., Rotenberg S.A., Borner C.M.B., and Weinstein I.B. Prog. Clin. Biol. Res. 340 (1990) 175
4. Sun X., and Rotenberg S.A. Cell Growth Differ. 10 (1999) 343
5. Sanz-Navares E., Fernandez N., Kazanietz M.G., and Rotenberg S.A. Cell Growth Differ. 12 (2001) 517
6. Hanauske A.R., Sundell K., and Lahn M. Curr. Pharm. Des. 10 (2004) 1923
7. Silva D. Curr. Cancer Drug Targets 4 (2004) 327
8. Chung S.H., Polgar J., and Reed G.L. J. Biol. Chem. 275 (2000) 25286
9. House C., and Kemp B.E. Science 238 (1987) 1726
10. Parker P.J., Coussens L., Totty N., Rhee L., Young S., Chen E., Stabel S., Waterfield M.D., and Ullrich A. Science 233 (1986) 853
11. Rotenberg S.A., Calogeropoulou T., Jaworski J.S., Weinstein I.B., and Rideout D. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 2490
12. Rotenberg S.A., Huang M.H., Zhu J., Su L., and Riedel H. Mol. Carcinog. 12 (1995) 42
13. Tammela P., Ekokoski E., Garcia-Horsman A., Talman V., Finel M., Tuominen R., and Vuorela P. Drug Dev. Res. 63 (2004) 76
14. Rotenberg, S. A.; Baker, A. D. U.S. Patent 2002114769, 2002.
15. Rotenberg S.A., Smiley S., Ueffing M., Krauss R.S., Chen L.B., and Weinstein B. Cancer Res. 50 (1990) 677
16. Qin D., Sullivan R., Berkowitz W.F., Bittman R., and Rotenberg S.A. J. Med. Chem. 43 (2000) 1413
17. Rotenberg S.A., and Sun X.-g. J. Biol. Chem. 273 (1998) 2390
18. Rotenberg S.A., Zhu J., Hansen H., Li X.-d., Sun X.-g., Michels C.A., and Riedel H. J. Biochem. 124 (1998) 756
19. Sullivan R.M., Stone M., Marshall J.F., Uberall F., and Rotenberg S.A. Mol. Pharmacol. 58 (2000) 729
20. Babbs M., Collier H.O.J., Austin W.C., Potter M.D., and Taylor E.P. J. Pharm. Pharmacol. 8 (1956) 110
21. Toshio A., Shozo K., and Sachiko K. Yakuzaigaku 26 (1966) 131
22. Toshio A., Shozo K., and Sachiko K. Yakuzaigaku 26 (1966) 189
23. Weiss M.J., Wong J.R., Ha C.S., Bleday R., Salem R.R., Steele G.D., and Chen L.B. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 5444
24. Zhuo S., and Allison W.S. Biochem. Biophys. Res. Commun. 152 (1988) 968
25. Bodden W.L., Palayoor S.T., and Hait W.N. Biochem. Biophys. Res. Commun. 135 (1986) 574
26. Galanakis D., Davis C.A., Herrero B.D.R., Ganellin C.R., Dunn P.M., and Jenkinson D.H. Bioorg. Med. Chem. Lett. 5 (1995) 559
27. Galanakis D., Davis C.A., Herrero B.D.R., Ganellin C.R., and Dunn P.M. J. Med. Chem. 38 (1995) 595
28. Galanakis D., Calder J.A.D., Ganellin C.R., Owen C.S., and Dunn P.M. J. Med. Chem. 38 (1995) 3536
29. Galanakis D., Davis C.A., Ganellin C.R., and Dunn P.M. J. Med. Chem. 39 (1996) 359
30. Galanakis D., Ganellin C.R., Malik S., and Dunn P.M. J. Med. Chem. 39 (1996) 3592
31. Cook N.S. Trends Pharmacol. Sci. 9 (1988) 21
32. Robertson D.W., and Steinberg M.I. J. Med. Chem. 33 (1990) 1529
33. Makler, M. T. PCT Int. Appl. PIXXD2 WO 9004644 A1 19900503, 1990.
34. The procedure was a modification of that described by. Backeberg O.G., and Marais J.L.C. J. Chem. Soc. (London) (1942) 381
35. Use of a methyl group to quaternize the head groups is a common practice in computational studies for this type of dimers.
36. 1 is that they come out negative even for N atoms with a formal plus charge. Electron-donating groups then make the Mulliken charges even more negative.
37. Compounds 13 and 14 were purchased from Aldrich.